rivastigminum 19.2 mg, 2-ethylhexylis acrylatis et vinylis acetatis polymerisatum, polyisobutylenum, silica colloidalis anhydrica, paraffinum perliquidum, Trägermaterial: polyethylenum/aluminium polyesterum, polyesterum, ad praeparationem pro 12.8 cm², cum liberatione 13.3 mg/24h.
Packungsbestandteile
Transdermale Pflaster
Active Agent
Dose
Rivastigmine
19.2 mg
BAG: Active Agent
Dose
Rivastigmine
19.2 mg
Inactive agents
Dose
additional_information
2-ethylhexylis Acrylatis
Ad Praeparationem
12.8 cm
Cum Liberatione
13.3mg / 24h
Paraffine Perliquide
Polyesterum
Polyethylenum/aluminium Polyesterum
Trägermaterial
Polyisobutylenum
Silica Colloidalis Anhydrica
Vinylis Acetatis Polymerisatum
Source
Data was imported : 07.12.2022
Swissmedic Registration :
Sequence :
Product name :
Registration owner: :
Product group :
Index Therapeuticus (BSV) :
Medication Code :
Date of registration :
Valid until :
Package number :
Show package size :
Commercial Form/Unit :
Swissmedic categorie. :
Active Agents :
Composition :
